Category: Biotech
8 founders, leaders highlight fintech and deep tech as Bristol’s top sectors
The U.K. is gaining in popularity as a great place to start a tech firm. The country is quickly catching up to China on the tech investment front, with VC investments reaching a record of $15 billion in 2020, according to TechNation. A global health crisis notwithstanding, London remained a…
Read More
Mobile dialysis startup eyes human trials in 2022 following encouraging animal study
This past year, three sheep in Canada have been wearing their kidneys on their sleeves. Or more aptly, in jackets on their fluffy backs. These three sheep are part of an ongoing animal study run by the Buffalo, New York-based startup Qidni Labs, a company pursuing waterless and mobile blood…
Read More
With $21M in funding, Code Ocean aims to help researchers replicate data-heavy science
Every branch of science is increasingly reliant on big data sets and analysis, which means a growing confusion of formats and platforms — more than inconvenient, this can hinder the process of peer review and replication of research. Code Ocean hopes to make it easier for scientists to collaborate by…
Read More
Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its…
Read More
Longevity startup Gero AI has a mobile API for quantifying health changes
Sensor data from smartphones and wearables can meaningfully predict an individual’s ‘biological age’ and resilience to stress, according to Gero AI. The ‘longevity’ startup — which condenses its mission to the pithy goal of “hacking complex diseases and aging with Gero AI” — has developed an AI model to predict…
Read More
2021 should be a banner year for biotech startups that make smart choices early
Michael B. Gray Contributor Michael B. Gray is partner and leader of the private equity, venture capital and growth companies practice, Neal Gerber Eisenberg. John Flavin Contributor Last year was a record 12 months for venture-backed biotech and pharma companies, with deal activity rising to $28.5 billion from $17.8 billion…
Read More